Spotlight Presentation to showcase four routes of synthesis of an approved siRNA therapeutic asset——Joint poster presentation with Bachem to ...

Presentation Date/Time: Saturday, December 7, 2024, 5:30 p.m. PT Presenting Speaker: Alissa Brandes, Ph.D.

- Initial data from the ongoing Phase 1b study evaluating R289, a dual IRAK1/4 inhibitor, in LR-MDS Initial data from the dose escalation phase using a July 15, 2024 data cutoff date indicate that ...

The poster presentation details are as follows: Session Name: 616. Acute Myeloid Leukemias: Investigational Drug and Cellular Therapies: Poster II Publication Number: 2881 Title: MP0533 (CD33 x CD123 ...

AstraZeneca and TotalEnergies are among the stocks that fell into undervalued territory. We sell different types of products and services to both investment professionals and individual investors ...

The poster to be presented at ASH 2024 will provide a clinical update of the ongoing first-in-human dose-escalation phase 1/2a study of MP0533 in patients with relapsed/refractory acute myeloid ...

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced upcoming presentations of six posters highlighting ...

Poster presentations across all programs, including updates from ongoing clinical studies and new translational data in ...

Eli Lilly and Company (NYSE: LLY) today announced that data from studies of Jaypirca® (pirtobrutinib), a non-covalent ...

Tempus Announces Nine Abstracts Accepted for Presentation at the 2024 Society for Immunotherapy of Cancer Annual Meeting ...